Boehm Marcus's Form 4/A amendment
AmendedVyant Bio, Inc. (VYNT) · filed Jul 1, 2021
- Accession no.
- 0001493152-21-015911
- Filed
- Jul 1, 2021
- Trade date
- Mar 30-Jun 30, 2021
- Filing delay
- 93 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Apr 1, 2021
This filing lists 7 non-derivative transactions. Open-market purchases total $37.2K. It was filed 93 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Boehm MarcusCIK 0001850698 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 30, 2021 | Common Stock, $0.0001 par value | JOtherAcquired | +93,786 | –F1 | – | 93,786 | Direct | |
| May 5, 2021 | Common Stock, $0.0001 par value | GGiftDisposed | −78,263 | $0.00 | $0 | 15,253 | Direct | |
| May 5, 2021 | Common Stock, $0.0001 par value | GGiftAcquired | +78,263 | $0.00 | $0 | 78,263 | Indirect | |
| May 10, 2021 | Common Stock, $0.0001 par value | GGiftDisposed | −15,523 | $0.00 | $0 | 0 | Direct | |
| May 10, 2021 | Common Stock, $0.0001 par value | GGiftAcquired | +15,523 | $0.00 | $0 | 93,786 | Indirect | |
| May 28, 2021 | Common Stock, $0.0001 par value | PPurchaseAcquired | +5,000 | $3.68 | +$18,400 | 98,786 | Indirect | |
| Jun 30, 2021 | Common Stock, $0.0001 par value | PPurchaseAcquired | +5,000 | $3.76F4 | +$18,800 | 103,786 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.
Referenced by the price of 1 transaction in Table I.
- F2
The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person under the Boehm Family Trust, Marcus & Kimberley Boehm Trustees on May 24, 2021.
- F3
Shares were previously reported as being directly held by reporting person.
- F4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.8099 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Referenced by the price of 1 transaction in Table I.
Remarks
This amended Form 4 is being filed to correct (i) the number of shares issued pursuant to the merger on March 30, 2021, (ii) reporting person's indirect purchase of shares (via a trust) on May 28, 2021 and (iii) the disclosure of shares previously owned directly that were transferred to a trust reported on the Form 4 filed July 1, 2021.